Chimeric Adeno-Associated Virus-Mediated Cardiovascular Reprogramming for Ischemic Heart Disease

Area of Science:

• Cardiovascular Biology
• Gene Therapy
• Regenerative Medicine

Background:

• Ischemic heart diseases lead to significant cardiomyocyte loss and cardiac fibrosis.
• Current treatments have limitations in promoting cardiac regeneration and preventing scar tissue formation.

Purpose of the Study:

• To develop a chimeric adeno-associated virus (AAV)-mediated strategy for cardiovascular reprogramming and regeneration.
• To assess the efficacy of combining AAV-GMT (Gata4, Mef2c, Tbx5) and AAV-Tβ4 in generating new cardiomyocytes and limiting fibrosis.

Main Methods:

• Utilized chimeric AAV vectors, specifically AAV-DJ, to deliver therapeutic genes.
• Employed a synergistic approach with AAV-GMT for cardiac reprogramming and AAV-Tβ4 for cardiac regeneration.
• Monitored the expression of cardiac-specific genes and fibrosis-related genes.

Main Results:

• AAV-GMT successfully upregulated cardiac-specific genes (Actc1, Gja1, Myh6, Ryr2, cTnT).
• AAV-GMT treatment led to a decrease in the expression of procollagen type I, a marker of fibrosis.
• AAV-Tβ4 enhanced the expression of GMT, supporting the synergistic therapeutic effect.

Conclusions:

• The developed chimeric AAV strategy offers a promising therapeutic approach for ischemic heart diseases.
• This method effectively generates new cardiomyocytes and mitigates collagen deposition in cardiac fibroblasts.
• The synergistic action of AAV-GMT and AAV-Tβ4 provides a novel cell reprogramming strategy for cardiac repair.